# Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

> **NCT00518895** · PHASE3 · COMPLETED · sponsor: **Genta Incorporated** · enrollment: 300 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** dacarbazine plus Genasense
- **DRUG:** dacarbazine plus placebo

## Key facts

- **NCT ID:** NCT00518895
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2011-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00518895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00518895, "Trial of Dacarbazine With or Without Genasense in Advanced Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00518895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*